The table below shows REGENERON PHARMACEUTICALS, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
$4.98B
$4.42B
$4.59B
$5.01B
$7.08B
$2.62B
Capital expenditure
-
-
-
-
-
-
Investing cash flow
-$629.10M
-$2.47B
-$3.19B
-$3.78B
-$5.38B
-$70.60M
Dividends paid
$370.30M
$0.00
$0.00
-
-
-
REGN operating cash flow (10-K history)
REGENERON PHARMACEUTICALS, INC. reported operating cash flow of $4.98B for fiscal year 2025. That is up 12.6% from $4.42B in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $1.49B (FY 2016) to $4.98B. Figures come from the company's audited annual reports as filed with the SEC.
